{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T10:23:57Z","timestamp":1748255037003,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s10157-022-02295-w","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T16:02:41Z","timestamp":1672156961000},"page":"288-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High-risk screening for Fabry disease in hemodialysis patients in Chiba Prefecture, Japan"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-7069","authenticated-orcid":false,"given":"Toshiyuki","family":"Imasawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Takayanagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimitoshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"2295_CR1","first-page":"3733","volume-title":"The metabolic and molecular bases of inherited disease","author":"RJ Desnick","year":"2001","unstructured":"Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase a deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 3733\u201374."},{"key":"2295_CR2","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry\u2019s disease: Ceramidetrihexosidase deficiency. N Engl J Med. 1967;276:1163\u20137.","journal-title":"N Engl J Med"},{"key":"2295_CR3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s10157-021-02058-z","volume":"25","author":"S Feriozzi","year":"2021","unstructured":"Feriozzi S, Rozenfeld P. Pathology and pathogenic pathways in Fabry nephropathy. Clin Exp Nephrol. 2021;25:925\u201334.","journal-title":"Clin Exp Nephrol"},{"key":"2295_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ. International collaborative Fabry disease study group Fabry disease study group. safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry\u2019s disease. N Engl J Med. 2001;345:9\u201316.","journal-title":"N Engl J Med"},{"key":"2295_CR5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf El Din U, Lourenco CM, Banikazemi M, Charrow J, Dasouki M, Finegold D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375:545\u201355.","journal-title":"N Engl J Med"},{"key":"2295_CR6","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1093\/ckj\/sfaa065","volume":"14","author":"A Ortiz","year":"2020","unstructured":"Ortiz A, Kanters S, Hamed A, DasMahapatra P, Poggio E, Maski M, Aguiar M, Ponce E, Jansen JP, Ayers D, Goldgrub R, Desnick RJ. Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis. Clin Kidney J. 2020;14:1136\u201346.","journal-title":"Clin Kidney J"},{"key":"2295_CR7","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jpeds.2010.02.012","volume":"156","author":"CL Marchesoni","year":"2010","unstructured":"Marchesoni CL, Roa N, Pardal AM, Neumann P, C\u00e1ceres G, Mart\u00ednez P, Kisinovsky I, Bianchi S, Tarabuso AL, Reisin RC. Misdiagnosis in Fabry disease. J Pediatr. 2010;156:828\u201331.","journal-title":"J Pediatr"},{"key":"2295_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13023-020-01494-6","volume":"15","author":"S Yoshida","year":"2020","unstructured":"Yoshida S, Kido J, Sawada T, Momosaki K, Sugawara K, Matsumoto S, Endo F, Nakamura K. Fabry disease screening in high-risk populations in Japan: a nationwide study. Orphanet J Rare Dis. 2020;15:220.","journal-title":"Orphanet J Rare Dis"},{"key":"2295_CR9","doi-asserted-by":"publisher","first-page":"136080","DOI":"10.1016\/j.neulet.2021.136080","volume":"760","author":"MP Wasserstein","year":"2021","unstructured":"Wasserstein MP, Orsini JJ, Goldenberg A, Caggana M, Levy PA, Breilyn M, Gelb MH. The future of newborn screening for lysosomal disorders. Neurosci Lett. 2021;760:136080.","journal-title":"Neurosci Lett"},{"key":"2295_CR10","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s10038-019-0633-1","volume":"64","author":"N Nakagawa","year":"2019","unstructured":"Nakagawa N, Sawada J, Sakamoto N, Takeuchi T, Takahashi F, Maruyama JI, Momosaki K, Nakamura K, Endo F, Hasebe N. High-risk screening for Anderson\u2013Fabry disease in patients with cardiac, renal, or neurological manifestations. J Hum Genet. 2019;64:891\u20138.","journal-title":"J Hum Genet"},{"key":"2295_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1502","volume":"8","author":"T Sawada","year":"2020","unstructured":"Sawada T, Kido J, Sugawara K, Matsumoto S, Takada F, Tsuboi K, Ohtake A, Endo F, Nakamura K. Detection of novel Fabry disease-associated pathogenic variants in Japanese patients by new born and high-risk screening. Mol Genet Genomic Med. 2020;8: e1502.","journal-title":"Mol Genet Genomic Med"},{"key":"2295_CR12","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.3390\/diagnostics11101779","volume":"11","author":"T Sawada","year":"2021","unstructured":"Sawada T, Kido J, Sugawara K, Nakamura K. High-risk screening for Fabry disease: a nationwide study in Japan and literature review. Diagnostics (Basel). 2021;11:1779.","journal-title":"Diagnostics (Basel)"},{"key":"2295_CR13","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1681\/ASN.2008080870","volume":"20","author":"M West","year":"2009","unstructured":"West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M, Barshop BA, Rhead W, Mensah R, Ries M, Schiffmann R. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol. 2009;20:1132\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"2295_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","volume":"64","author":"S Nakao","year":"2003","unstructured":"Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, Tei C, Desnick RJ. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype. Kidney Int. 2003;64:801\u20137.","journal-title":"Kidney Int"},{"key":"2295_CR15","doi-asserted-by":"publisher","first-page":"11089","DOI":"10.1038\/s41598-018-29432-4","volume":"8","author":"D Azpiazu","year":"2018","unstructured":"Azpiazu D, Gonz\u00e1lez-Parra E, Egido J, Villa-Bellosta R. Hydrolysis of extracellular pyrophosphate increases in post-hemodialysis plasma. Sci Rep. 2018;8:11089.","journal-title":"Sci Rep"},{"key":"2295_CR16","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/eci.12297","volume":"44","author":"AM Schulz","year":"2014","unstructured":"Schulz AM, Terne C, Jankowski V, Cohen G, Schaefer M, Boehringer F, Tepel M, Kunkel D, Zidek W, Jankowski J, European Uremic Toxin Work Group (EUTox). Modulation of NADPH oxidase activity by known uraemic retention solutes. Eur J Clin Invest. 2014;44:802\u201311.","journal-title":"Eur J Clin Invest"},{"key":"2295_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/gim.2018.31","volume":"21","author":"H Maruyama","year":"2019","unstructured":"Maruyama H, Miyata K, Mikame M, Taguchi A, Guili C, Shimura M, Murayama K, Inoue T, Yamamoto S, Sugimura K, Tamita K, Kawasaki T, Kajihara J, Onishi A, Sugiyama H, Sakai T, Murata I, Oda T, Toyoda S, Hanawa K, Fujimura T, Ura S, Matsumura M, Takano H, Yamashita S, Matsukura G, Tazawa R, Shiga T, Ebato M, Satoh H, Ishii S. Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. Genet Med. 2019;21:44\u201352.","journal-title":"Genet Med"},{"issue":"8","key":"2295_CR18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","volume":"83","author":"R Dobrovolny","year":"2005","unstructured":"Dobrovolny R, Dvorakova L, Ledvinova J, Magage S, Bultas J, Lubanda JC, Elleder M, Karetova D, Pavlikova M, Hrebicek M. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase a gene in the Czech and Slovak population. J Mol Med (Berl). 2005;83(8):647\u201354.","journal-title":"J Mol Med (Berl)"},{"key":"2295_CR19","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.xkme.2021.01.006","volume":"3","author":"S Manabe","year":"2021","unstructured":"Manabe S, Mochizuki T, Sato M, Kataoka H, Taneda S, Honda K, Uchida K, Nitta K. Lupus nephritis and hydroxychloroquine-associated zebra bodies: not just in Fabry disease. Kidney Med. 2021;3:442\u20136.","journal-title":"Kidney Med"},{"key":"2295_CR20","doi-asserted-by":"publisher","first-page":"100773","DOI":"10.1016\/j.ymgmr.2021.100773","volume":"28","author":"T Tsukimura","year":"2021","unstructured":"Tsukimura T, Shiga T, Saito K, Ogawa Y, Sakuraba H, Togawa T. Does administration of hydroxychloroquine\/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice? Mol Genet Metab Rep. 2021;28:100773.","journal-title":"Mol Genet Metab Rep"},{"key":"2295_CR21","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s13730-021-00612-y","volume":"10","author":"H Shimohata","year":"2021","unstructured":"Shimohata H, Miyake Y, Yoshida Y, Usui J, Mori T, Sohara E, Uchida S, Hirayama K, Kobayashi M. LMX1B-associated nephropathy that showed myelin figures on electron microscopy. CEN Case Rep. 2021;10:588\u201391.","journal-title":"CEN Case Rep"},{"key":"2295_CR22","first-page":"91","volume":"4","author":"H Sakuraba","year":"2015","unstructured":"Sakuraba H, Tsukimura T, Tanaka T, Togawa T, Takahashi N, Mikami D, Wakai S, Akai Y. Clinical and biochemical investigation of male patients exhibiting membranous cytoplasmic bodies in biopsied kidney tissues; a pitfall in diagnosis of Fabry disease. J Nephropathol. 2015;4:91\u20136.","journal-title":"J Nephropathol"},{"key":"2295_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s41100-020-00286-9","volume":"6","author":"K Nitta","year":"2020","unstructured":"Nitta K, Goto S, Masakane I, Hanafusa N, Taniguchi M, Hasegawa T, Nakai S, Wada A, Hamano T, Hoshino J, Joki N. Annual dialysis data report for 2018, JSDT renal data registry: survey methods, facility data, incidence, prevalence, and mortality. Ren Replace Ther. 2020;6:41.","journal-title":"Ren Replace Ther"},{"key":"2295_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/ndt\/gfaa324","volume":"37","author":"A Nagata","year":"2021","unstructured":"Nagata A, Nasu M, Kaida Y, Nakayama Y, Kurokawa Y, Nakamura N, Shibata R, Hazama T, Tsukimura T, Togawa T, Saito S, Sakuraba H, Fukami K. Screening of Fabry disease in patients with chronic kidney disease in Japan. Nephrol Dial Transplant. 2021;37:115\u201325.","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-022-02295-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-022-02295-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-022-02295-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T17:23:07Z","timestamp":1677172987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-022-02295-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["2295"],"URL":"https:\/\/doi.org\/10.1007\/s10157-022-02295-w","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"type":"print","value":"1342-1751"},{"type":"electronic","value":"1437-7799"}],"subject":[],"published":{"date-parts":[[2022,12,27]]},"assertion":[{"value":"11 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and with the approval by the ethics committee and institutional review board of Chiba-Higashi National Hospital (No. R1-13) and each hospital participated in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was obtained from all the individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}